

NYRx Drug Coverage Overview: Yeztugo®

November 6, 2025

NYRx Drug Utilization Review Program

Effective November 6, 2025, Yeztugo® will be covered as a pharmacy benefit by NYRx, the Medicaid Pharmacy Program, in addition to being covered by the Medicaid managed care medical benefit as a [Practitioner-Administered Drug](#) (PAD). Prescribers can choose the option that works best for them and their patients.

Yeztugo is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents. Confirmation of a negative HIV-1 test will be required prior to each dose.

For more information about Yeztugo and other [HIV PrEP Agents](#), please review the prior authorization (PA) requirements as outlined in the [Drug Utilization Review section](#) of the [NYRx Medicaid Pharmacy Program document](#).

What Pharmacy Providers and Prescribers Need to Do

For patients starting therapy, the initial dose schedule of Yeztugo consists of a combination of oral tablets and subcutaneous injection. To prevent pharmacy claim denial, it is important for the pharmacy to submit the claim for both oral and subcutaneous products on the same date of service.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Prior Authorization Submission Guide](#)
- [New York State Medicaid Practitioner-Administered Drugs FAQ](#)
- [NYRx Drug Class Coverage Overview: HIV Pre-Exposure Prophylaxis Agents](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.